申请人:Kiss Zoltan
公开号:US20070060634A1
公开(公告)日:2007-03-15
A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.
一类常见的化合物,通常含有三烷基铵基团,已被合成并作为抗癌化合物进行了表征。该类化合物的代表物是N,N-二乙基-N-甲基-2-[(9-氧代-9H-噻二苯并-2-基)甲氧基]乙胺碘化物(CCDTHT),在各种肿瘤模型中显示出降低肿瘤体积、增强其他化疗药物(包括顺铂)的效果、减少化疗引起的体重损失以及增加共同接受有毒量顺铂的动物的生存率。当与人类蛋白质胎盘碱性磷酸酶一起给动物施用时,CCDTHT对肿瘤体积、体重和生存率的影响更大。这些含有三烷基铵基团和碱性磷酸酶的化合物,特别是与彼此和其他治疗方法结合使用时,可用于治疗癌症和其他细胞增殖性疾病。